公开(公告)号：US20230303552A1

公开(公告)日：2023-09-28

申请号：US18002004

申请日：2021-06-18

Applicant: Vanderbilt University

Inventor： Andrew S. Felts ,  Changho Han ,  Rory A. Capstick ,  Douglas L. Orsi ,  David L. Whomble ,  Craig W. Lindsley ,  P. Jeffrey Conn

IPC: C07D417/14 ,  C07D405/14 ,  C07D498/04 ,  C07D417/12 ,  C07D471/04

CPC classification number: C07D417/14 ,  C07D405/14 ,  C07D417/12 ,  C07D471/04 ,  C07D498/04

Abstract: Arylsulfonamides of carboxamido-piperidines, -pyrrolidines, and -azetidines, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment of psychiatric disorders such as substance-related misuse, substance- related disorder relapse, anxiety, depression, and psychosis.

公开(公告)号：US20240208983A1

公开(公告)日：2024-06-27

申请号：US18553398

申请日：2022-04-01

Applicant: Vanderbilt University

Inventor： Craig W. Lindsley ,  P. Jeffrey Conn ,  Andrew S. Felts ,  Rory A. Capstick ,  David L. Whomble

IPC: C07D487/04 ,  A61K31/4375 ,  A61P25/24 ,  A61P25/28

CPC classification number: C07D487/04 ,  A61K31/4375 ,  A61P25/24 ,  A61P25/28

Abstract: Described are 6-aryl [1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject.

公开(公告)号：US20240390350A1

公开(公告)日：2024-11-28

申请号：US18691641

申请日：2022-09-14

Applicant: Vanderbilt University

Inventor： Craig W. Lindsley ,  Jeffrey P. Conn ,  Andrew S. Felts ,  Rory A. Capstick ,  Kayla J. Temple ,  Anna E. Ringuette ,  Scott H. Henderson ,  David L. Whomble

IPC: A61K31/4439 ,  A61K31/444 ,  C07D401/12 ,  C07D417/12

Abstract: Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US20240199640A1

公开(公告)日：2024-06-20

申请号：US18550996

申请日：2022-03-18

Applicant: Vanderbilt University

Inventor： Craig W. Lindsley ,  P. Jeffrey Conn ,  Andrew S. Felts ,  Rory A. Capstick ,  David L. Whomble ,  Jeremy Coleman ,  Upendra Rathnayake ,  Daren Engers

IPC: C07D498/04 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/519 ,  A61K31/5365 ,  C07D209/46 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04

CPC classification number: C07D498/04 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/519 ,  A61K31/5365 ,  C07D209/46 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04

Abstract: Described are 6-aryl isoindolin-1-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject.

公开(公告)号：US20230183237A1

公开(公告)日：2023-06-15

申请号：US17998901

申请日：2021-05-21

Applicant: Vanderbilt University

Inventor： Craig W. Lindsley ,  Carrie K. Jones ,  P. Jeffrey Conn ,  Changho Han ,  Andrew S. Felts ,  Douglas L. Orsi ,  Julie L. Engers ,  Jinming Li ,  Rory A. Capstick ,  David L. Whomble ,  Kayla J. Temple

IPC: C07D471/04 ,  C07D417/14 ,  C07D405/14 ,  C07D513/04 ,  C07D495/04 ,  C07D487/04 ,  C07D491/048 ,  C07D519/00 ,  C07D401/14 ,  C07D413/14 ,  C07D498/04 ,  C07D401/12

CPC classification number: C07D471/04 ,  C07D417/14 ,  C07D405/14 ,  C07D513/04 ,  C07D495/04 ,  C07D487/04 ,  C07D491/048 ,  C07D519/00 ,  C07D401/14 ,  C07D413/14 ,  C07D498/04 ,  C07D401/12 ,  C07B2200/05

Abstract: Arylsulfonamides of 4-heteroaryl-piperidines, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment of psychiatric disorders such as substance-related misuse, substance-related disorder relapse, anxiety, depression, and psychosis.